- 2Q Sales Performance: Ipsen reported sales of EU836.9 million, which is close to the estimate of EU842 million.
- Upgraded 2024 Financial Guidance: Total-sales growth is now expected to be greater than 7.0% at constant exchange rates (CER), up from the prior guidance of greater than 6.0% at CER.
- Core Operating Margin: The expected core operating margin is upgraded to greater than 30.0% of total sales, up from the previous forecast of around 30%.
- Strategic Progress: CEO David Loew highlighted the strong results in the first half, indicating robust growth prospects for the medium term.
- Analyst Recommendations: The stock has 7 buy ratings, 11 hold ratings, and 0 sell ratings.
A look at Ipsen SA Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Investment analysts are keeping a close eye on Ipsen SA, a company that manufactures and markets medical drugs for various disease areas. With a mixed bag of Smart Scores, Ipsen SA is in a position of moderate strength. While its Value and Growth scores stand at a neutral level of 3, indicating stability in these areas, its Dividend score is slightly lower at 2, suggesting room for improvement. However, the company shines in terms of Resilience and Momentum, scoring a solid 4 in both categories. This bodes well for Ipsen SA‘s ability to weather challenges and maintain positive momentum in the market.
Overall, Ipsen SA‘s long-term outlook appears promising with a strong emphasis on resilience and growth continuity. The company’s focus on producing drugs for targeted disease areas like oncology, endocrinology, and neuromuscular disorders positions it well for future success. Investors are likely to view Ipsen SA as a company with solid potential, especially considering its noteworthy scores in resilience and momentum. While there may be areas for improvement, Ipsen SA‘s overall Smart Scores paint a picture of a company with a stable foundation and positive forward momentum in the pharmaceutical industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
